The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2019 | Magrolimab plus aza: phase 1b data in MDS/AML
Magrolimab is a first-in-class antibody targeting CD47, a macrophage immune checkpoint and “don’t eat me” signal on malignant cells. Blocking CD47 with magrolimab may enable the body’s immune system to find and eliminate these cells. David Sallman, MD, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, discusses the results from the ongoing phase 1 trial (NCT03248479) of magrolimab in combination with azacitidine in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
